Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

3.920 +0.010 (+0.26%)
Streaming Delayed Price Updated: 3:26 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aprea Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 13, 2021
Upgrades For ACV Auctions Inc (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Biolase (NASDAQ:BIOL) stock moved upwards by 42.49% to $0.9 during Friday's pre-market session. The company's market cap stands at $135.3 million. As per... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) shares rose 20.37% to $3.9 during Thursday's pre-market session. The company's market cap stands at $37.8 million.... 
Via Benzinga
Why Aprea Therapeutics Shares Are Surging Today
Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading hi... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study
After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold... 
Via Benzinga
Exposures Product Safety
Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials
The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with... 
Via Benzinga
Exposures Product Safety
Analyzing Aprea Therapeutics's Unusual Options Activity
On Wednesday, shares of Aprea Therapeutics (NASDAQ:APRE) saw unusual options activity. After the option alert, the stock price moved up to $5.2. Sentiment: NEUTRAL Option Type:... 
Via Benzinga
Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant
Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Alterity Therapeutics (NASDAQ:ATHE 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Midatech Pharma (NASDAQ:MTP) stock rose 36.76% to $2.79 during Thursday's regular session. Midatech Pharma's stock is trading at a volume of 69.8 million... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront. Orphazyme A/S... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Federal Reserve Maintains Interest Rates
Toward the end of trading Wednesday, the Dow traded down 0.92% to 33,983.29 while the NASDAQ fell 0.68% to 13,977.59. The S&P also fell, dropping 0.74% to 4,215.21. The U.S.... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 72.49% to $17.34 during Wednesday's regular session. As of 12:31 EST, Orphazyme's stock is trading at a... 
Via Benzinga
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT)... 
Via Benzinga
APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today
Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. 
Via InvestorPlace
Mid-Day Market Update: Dow Falls 40 Points; Aprea Therapeutics Shares Surge
Midway through trading Wednesday, the Dow traded down 0.12% to 34,259.48 while the NASDAQ rose 0.20% to 14,100.31. The S&P also fell, dropping 0.05% to 4,244.41. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Opthea Limited (NASDAQ: OPT) shares surged 50.7% to $13.28. The company recently appointed Mrs. Karen Adams as Vice President of Finance and Company Secretary. Kindred... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Elanco Animal Health To Acquire Kindred Biosciences
Following the market opening Wednesday, the Dow traded down 0.15% to 34,247.35 while the NASDAQ rose 0.36% to 14,123.49. The S&P also fell, dropping 0.01% to 4,246.07. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kindred Biosciences (NASDAQ:KIN) shares moved upwards by 45.26% to $9.21 during Wednesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 24 stocks hit new 52-week lows. Facts of Interest: American Well (NYSE:AMWL) was the largest firm by market cap to set a new... 
Via Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Friday
Friday's morning session saw 17 companies set new 52-week lows. Key Facts: Beyond Meat (NASDAQ:BYND) was the largest firm on a market cap basis to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.